Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Return on Equity (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Return on Equity for 11 consecutive years, with 1.02% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Equity rose 111.0% year-over-year to 1.02%, compared with a TTM value of 1.02% through Sep 2025, up 111.0%, and an annual FY2024 reading of 0.5%, down 1797.0% over the prior year.
  • Return on Equity was 1.02% for Q3 2025 at Avalo Therapeutics, down from 0.41% in the prior quarter.
  • Across five years, Return on Equity topped out at 2.74% in Q2 2023 and bottomed at 6.05% in Q3 2023.
  • Average Return on Equity over 5 years is 0.28%, with a median of 0.01% recorded in 2021.
  • The sharpest move saw Return on Equity crashed -607bps in 2023, then skyrocketed 392bps in 2024.
  • Year by year, Return on Equity stood at 0.0% in 2021, then skyrocketed by 2042bps to 0.02% in 2022, then tumbled by -17435bps to 2.87% in 2023, then skyrocketed by 84bps to 0.46% in 2024, then plummeted by -123bps to 1.02% in 2025.
  • Business Quant data shows Return on Equity for AVTX at 1.02% in Q3 2025, 0.41% in Q2 2025, and 0.57% in Q1 2025.